— Published date: 6/2/2026
Value Proposition: VLA4 inhibitors that significantly mobilize hematopoietic stem cells from bone marrow.
Technology Description
Researchers at Washington University in St. Louis have developed novel VLA4 inhibitors for mobilizing hematopoietic stem cells in peripheral …
— Published Date: 5/13/2025
Value Proposition: An innovative therapy leveraging unique chimeric antigen receptors (CAR) to specifically target Fc receptor-like 5 (FCRL5), enabling the precise elimination of FCRL5-expressing cells to treat multiple myeloma and other cancers.
Technology Description
…
— Value Proposition: Engineered iNKT cells with potential as a “universal” source of immune effector cells to treat cancer.
Technology Description
Researchers at Washington University in St. Louis have developed a new composition of matter that uses gene-edited invariant natural kill…
— Technology Description
Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…
— Technology Description:
Researchers at Washington University in St. Louis have developed a biomarker screening assay to predict which patients receiving CAR T cell therapy will experience neurotoxicity. Patients can be screened well in advance of receiving the T cell therapy with a simple serum as…
— Technology Description
A team of researchers, led by John DiPersio and Matthew Cooper at Washington University in St. Louis, have identified a small molecule kinase inhibitor capable of mitigating cytokine release syndrome following CAR-T cell therapy. PI3K inhibitors can suppress production of IL-…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
